GlassScriptPhysician profile
Elaine S Davidson
NPI 1093705022
$1,883.40
in general payments reported to CMS, 2019-2025
30 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2021: $11.37 · 2022: $26.24 · 2023: $14.67 · 2024: $605 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.05 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $251.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $183.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $171.10 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $116.27 | 2024-2025 | |
| Exact Sciences Corporation | $90.84 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $85.06 | 2024-2025 | |
| Lilly USA, LLC | $72.31 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $67.05 | 2024 | Yupelri |
| Corcept Therapeutics | $61.15 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $60.07 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $59.70 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $46.52 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $38.80 | 2025 | Eliquis |
| Abbott Laboratories | $34.72 | 2024-2025 | Eterna, Proclaim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.64 | 2024-2025 | Spravato |
| Vertex Pharmaceuticals Incorporated | $24.78 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.74 | 2024 | Amvuttra |
| Dexcom, INC. | $21.63 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $21.25 | 2025 | |
| Stryker Corporation | $20.85 | 2024 | Triathlon, Mako |
| Recor Medical INC | $19.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Takeda Pharmaceuticals U.S.A., INC. | $17.70 | 2024 | Trintellix |
| Organon LLC | $16.75 | 2025 | Nexplanon |
| Abbvie INC. | $14.67 | 2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $11.94 | 2019 | |
| Corium, LLC | $8.80 | 2025 | Azstarys |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.